Cardiac Effects of Moxonidine in Spontaneously Hypertensive Obese Rats
- 1 December 2003
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1009 (1), 244-250
- https://doi.org/10.1196/annals.1304.030
Abstract
Moxonidine, an imidazoline receptor agonist that acts centrally to inhibit sympathetic activity, has been shown to reduce effectively blood pressure, fasting insulin levels, and free fatty...This publication has 26 references indexed in Scilit:
- Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts.JCI Insight, 1998
- CURRENT STATUS OF PUTATIVE IMIDAZOLINE (I1) RECEPTORS AND RENAL MECHANISMS IN RELATION TO THEIR ANTIHYPERTENSIVE THERAPEUTIC POTENTIALClinical and Experimental Pharmacology and Physiology, 1996
- Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky ratNature Genetics, 1996
- Mechanical and neuroendocrine regulation of the endocrine heartCardiovascular Research, 1996
- The role of the peripheral sympathetic nervous system in the natriuresis following central administration of an I1 imidazoline agonist, moxonidineBritish Journal of Pharmacology, 1995
- Natriuretic Peptides Inhibit DNA Synthesis in Cardiac FibroblastsHypertension, 1995
- Structural remodeling in hypertensive heart disease and the role of hormones.Hypertension, 1994
- I1-Imidazoline-Receptor Agonists in the Treatment of Hypertension: An Appraisal of Clinical ExperienceJournal of Cardiovascular Pharmacology, 1994
- Cardiac hypertrophy. Mechanical, neural, and endocrine dependence.Circulation, 1991
- Radioimmunoassay for atrial natriuretic factorInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1987